Cardiovascular diseases, chronic kidney disease (CKD) and metabolic conditions frequently occur in the same individual and may share common pathophysiological pathways of disease onset and progression ...

The comparative effectiveness of finerenone and spironolactone in chronic kidney disease (CKD) with type 2 diabetes (T2D) remains unclear. Here we show, using a target trial emulation on global ...

The nonsteroidal mineralocorticoid receptor antagonist finerenone (Kerendia) unexpectedly showed that it might protect against incident infective pneumonia and COVID-19. The finding was based on ...

Researchers from National Taiwan University Hospital and collaborating institutions have demonstrated that finerenone, a new-generation nonsteroidal mineralocorticoid receptor antagonist (MRA), ...

The nonsteroidal mineralocorticoid receptor antagonist finerenone has been reported to improve kidney and cardiovascular outcomes in persons with type 2 diabetes and chronic kidney disease (CKD). The ...

Finerenone, a nonsteroidal, selective mineralocorticoid receptor antagonist, reduced albuminuria in short-term trials involving patients with chronic kidney disease (CKD) and type 2 diabetes. However, ...

New signals of a potential additive benefit from the nonsteroidal mineralocorticoid antagonist finerenone (Kerendia) and a sodium-glucose cotransporter 2 (SGLT2) inhibitor in patients with type 2 ...

Finerenone reduced the combined primary endpoint of risk of chronic kidney disease progression, kidney failure or kidney death versus placebo when added to standard of care Approximately twenty-nine ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. The FINE-ONE trial assessed finerenone use by adults ...

A series of major studies has shown that finerenone preserves kidney function, reduces cardiovascular risk, and improves survival across a much broader range of patients with chronic kidney disease ...

(Glasgow, Scotland) Finerenone significantly slowed kidney function decline and reduced the risk of cardiovascular-kidney outcomes in adults with non-diabetic chronic kidney disease (CKD), according ...

The appraisal committee considered evidence submitted by Bayer, a review of this submission by the evidence review group (ERG), and responses from stakeholders. See the committee papers for full ...